EEF2K and early-onset autosomal dominant Alzheimer disease: High levels of phosphorylated eEF2 have been described in Alzheimer disease [51, 52], Parkinson disease [48] and genetic epilepsy [18] and it has also been reported that inhibition of eEF2K activity ameliorate the pathology [18, 47, 51, 52].